The influence of CYP2C19 polymorphism on the eradication of Helicobacter pylori:: A randomized study of lansoprazole and rabeprazole

被引：0
|
作者：
Jung, H. Y. [1 ]
Song, H. J. [1 ]
Choi, K. D. [1 ]
Chung, J. W. [1 ]
Kim, D. H. [1 ]
Kim, J. H. [1 ]
机构：
[1] Asan Med Ctr, Seoul, South Korea
来源：
HELICOBACTER | 2007年 / 12卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：429 / 429
页数：1
相关论文
共 50 条
  • [21] Zonalized therapy for Helicobacter pylori eradication depending on CYP2C19 polymorphisms
    Galvis, A. Arevalo
    Rangel, A. Trespalacios
    Regino, W. Otero
    HELICOBACTER, 2017, 22
  • [22] Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan
    Miki, I
    Aoyama, N
    Sakai, T
    Shirasaka, D
    Wambura, CM
    Maekawa, S
    Kuroda, K
    Tamura, T
    Kita, T
    Sakaeda, T
    Okumura, K
    Kasuga, M
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2003, 15 (01) : 27 - 33
  • [23] Genetic polymorphism of CYP2C19 in a Jordanian population: influence of allele frequencies of CYP2C19*1 and CYP2C19*2 on the pharmacokinetic profile of lansoprazole
    Zalloum, Imad
    Hakooz, Nancy
    Arafat, Tawfiq
    MOLECULAR BIOLOGY REPORTS, 2012, 39 (04) : 4195 - 4200
  • [24] Genetic polymorphism of CYP2C19 in a Jordanian population: influence of allele frequencies of CYP2C19*1 and CYP2C19*2 on the pharmacokinetic profile of lansoprazole
    Imad Zalloum
    Nancy Hakooz
    Tawfiq Arafat
    Molecular Biology Reports, 2012, 39 : 4195 - 4200
  • [25] CYP2C19 GENOTYPES AND FUTURE APPLICATIONS IN PERSONALIZED THERAPIES FOR HELICOBACTER PYLORI ERADICATION
    Arevalo, A.
    Trespalacios, A.
    Otero, W.
    Mercado, M.
    HELICOBACTER, 2014, 19 : 94 - 94
  • [26] Rabeprazole experience in Korea;: focus on CYP2C19 polymorphism
    Park, SH
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2005, 20 : S20 - S21
  • [27] IMPROVEMENTS IN HELICOBACTER PYLORI ERADICATION RATES THROUGH CLINICAL CYP2C19 GENOTYPING
    Tamura, Takashi
    Kurata, Mio
    Inoue, Shigeru
    Kondo, Takaaki
    Goto, Yasuyuki
    Kamiya, Yoshikazu
    Kawai, Sayo
    Hamajima, Nobuyuki
    NAGOYA JOURNAL OF MEDICAL SCIENCE, 2011, 73 (1-2): : 25 - 31
  • [28] The effect of rabeprazole and orneprazole-based triple therapy on eradication of Helicobacter pylori and its correlation to Cyp2C19 genetic polymorphisms
    Li, YY
    Wang, H
    Jiang, YJ
    Nie, YQ
    GASTROENTEROLOGY, 2005, 128 (04) : A431 - A431
  • [29] Importance of genetic polymorphism of s-mephenytoin-4'-hydroxylase(CYP2C19) in eradication of Helicobacter pylori.
    Nisijima, T
    Endo, Y
    Ota, S
    Fujiwara, K
    GASTROENTEROLOGY, 2000, 118 (04) : A1284 - A1284
  • [30] Influence of clarithromycin on the pharmacokinetics/pharmacodynamics of lansoprazole in relation to CYP2C19 polymorphism.
    Sohn, DR
    Kim, HK
    Kwon, JT
    Ishizaki, T
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 67 (02) : 160 - 160
12345